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The serine hydrolase a/b-hydrolase domain 6
(ABHD6) hydrolyzes the most abundant endocanna-
binoid (eCB) in the brain, 2-arachidonoylglycerol
(2-AG), and controls its availability at cannabinoid re-
ceptors. We show that ABHD6 inhibition decreases
pentylenetetrazole (PTZ)-induced generalized tonic-
clonic and myoclonic seizure incidence and severity.
This effect is retained inCnr1/ orCnr2/mice, but
blocked by addition of a subconvulsive dose of
picrotoxin, suggesting the involvement of GABAA re-
ceptors. ABHD6 inhibition also blocked spontaneous
seizures in R6/2 mice, a genetic model of juvenile
Huntington’s disease known to exhibit dysregulated
eCB signaling. ABHD6 blockade retained its antiepi-
leptic activity over chronic dosing and was not
associated with psychomotor or cognitive effects.
While the etiology of seizures in R6/2 mice remains
unsolved, involvement of the hippocampus is sug-
gested by interictal epileptic discharges, increased
expression of vGLUT1 but not vGAT, and reduced
Neuropeptide Y (NPY) expression. We conclude
that ABHD6 inhibition may represent a novel antiep-
ileptic strategy.
INTRODUCTION
In the brain, a major role of the eCB signaling system is to control
presynaptic neurotransmitter release (Di Marzo, 2011; Katona
and Freund, 2012). This system comprises the CB1 and CB2 re-ceptors and two main eCBs, anandamide and 2-AG, which are
produced and inactivated by distinct lipases and hydrolases,
respectively. We recently demonstrated that the serine hydro-
lase ABHD6 is a bona fide member of the eCB signaling system
that controls the availability of 2-AG, but not anandamide, at CB1
receptors (Marrs et al., 2011, 2010). Unlike other neurotransmit-
ters that are synthesized and stored in synaptic vesicles for
release, eCBs are produced on-demand in response to synaptic
activity (Di Marzo et al., 1994; Stella and Piomelli, 2001; Stella
et al., 1997). In neurons, ABHD6 is located postsynaptically, at
the site of 2-AG synthesis, where it fine-tunes the stimulated
production of 2-AG and the resulting activation of presynaptic
CB1 cannabinoid receptors (Marrs et al., 2011, 2010). Because
they rely on stimulated production of 2-AG, ABHD6 inhibitors
augment 2-AG availability with spatiotemporal selectivity (Ahn
et al., 2008; Blankman et al., 2007; Marrs et al., 2010). Therefore,
this enzyme represents a possible molecular hub that controls
the 2-AG/CB1 arm of eCB signaling (Stella, 2012). Recent studies
suggest that 2-AG may also act at GABAA receptors (Baur et al.,
2013; Sigel et al., 2011), and since both GABAA and ABHD6 are
located postsynaptically, the availability of 2-AG at GABAA re-
ceptors might be regulated by ABHD6 activity.
Epilepsy is a common condition that is refractory to current
therapies in approximately 30% of patients and is associated
with pathologic cortical excitability (Kwan and Brodie, 2000).
Current antiepileptic drugs target voltage-gated ion channels
to reduce neuronal excitability either directly or via modulation
of synaptic transmission. However, the therapeutic benefit of
these treatments is limited by a lack of efficacy in some patients,
as well as by their side-effect profiles, underlining the need for
developing new pharmacological strategies for the treatment
of epilepsy. Targeting neuromodulatory signaling systems (like
eCB signaling) that control endogenous homeostatic mecha-
nisms in a state-dependent manner may provide greater efficacyNeuron 83, 361–371, July 16, 2014 ª2014 Elsevier Inc. 361
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receptors reduce glutamatergic synaptic activity and protect
rodents against chemically induced seizures (Chen et al., 2007;
Lafourcade et al., 2007; Marsicano et al., 2003; Rudenko et al.,
2012), although paradoxical mechanisms whereby eCBs have
proconvulsant effects have also been described (Clement
et al., 2003). Inhibitors of eCB hydrolysis retain the ability to
reduce glutamatergic synaptic activity, but unlike CB1 receptor
agonists, these inhibitors rely on stimulated production of ligand
(eCBs) and thus selectively augment CB1 signaling at active syn-
apses. Among eCB hydrolases, ABHD6 is unique because its
postsynaptic location allows for the control of 2-AG availability
despite its low intrinsic activity compared to monoacylglycerol
lipase (MGL), the primary brain 2-AG hydrolase that controls
the bulk of 2-AG levels (Blankman et al., 2007; Marrs et al.,
2010). Thus, whereas MGL controls 2-AG levels at presynaptic
terminals, ABHD6 fine-tunes the activity-dependent production
of 2-AG at active synapses.
We hypothesized that ABHD6 blockade by WWL123, a brain-
penetrant selective inhibitor, would protect against PTZ-induced
epileptiform seizures without resulting in overt psychomotor
effects. Chemically induced seizure models represent a typical
initial drug-screening platform and provide predictive power for
the discovery of antiepileptic drugs (White, 2003). However,
this approach may miss compounds that could be effective
against specific epilepsies, including therapy-resistant seizures,
and have the drawback of inducing seizures in otherwise healthy
mice (Bialer and White, 2010; Smith et al., 2007). Based on this
rationale, we sought to test the ability of ABHD6 blockade to
control seizures in a genetic seizure model known to be associ-
ated with impaired eCB signaling. Specifically, R6/2mice display
both spontaneous and audiogenic seizures (Cepeda-Prado
et al., 2012; Mangiarini et al., 1996) and reproduce the profound
dysregulation of eCB signaling described in Huntington’s dis-
ease (HD) patients (Bisogno et al., 2008; Centonze et al.,
2005). R6/2 mice have both decreased 2-AG availability
(Bisogno et al., 2008) and CB1 receptor downregulation in select
neuronal populations (Dowie et al., 2009; Glass et al., 2000,
1993; Horne et al., 2013). Here, too, we hypothesized that
ABHD6 inhibition would prevent spontaneous seizures in R6/2
mice by augmenting 2-AG signaling.
RESULTS
Pharmacokinetic Profile and Target Engagement of
WWL123 and SR141716
To study the role of in vivo ABHD6 blockade in seizure incidence,
we first validated our pharmacological approach. WWL123 is a
carbamate (Figure S1A available online) that was discovered in
a screen of 70+ serine hydrolases as a specific inhibitor of
ABHD6 (IC50 = 0.43 mM), and in vivo dose-response studies iden-
tified 10 mg/kg as an optimal treatment dose (Bachovchin et al.,
2010). To confirm these findings, we dosed C57BL/6 mice with
vehicle or WWL123 (10 mg/kg, i.p.) and 4 hr later prepared ho-
mogenized cortical samples for activity-based protein profiling
(ABPP) to verify that WWL123 crosses the blood-brain barrier
and inhibits ABHD6 in brain parenchyma. We found that this
treatment reduced ABHD6 labeling by the FP-rhodamine and362 Neuron 83, 361–371, July 16, 2014 ª2014 Elsevier Inc.the HT-01 probe (Hsu et al., 2012, 2013a, 2013b), both of which
label serine hydrolases in an activity-dependent manner (Fig-
ure S1B and S1C). Importantly, WWL123 treatment did not affect
the labeling of other serine hydrolases, such as fatty acid amide
hydrolase (FAAH) and monoacylglycerol lipase (MGL), further
validating the selectivity of this inhibitor for ABHD6.
Similarly, we studied the pharmacokinetic profile of the CB1
antagonist SR141716 (SR1) and found that subcutaneous (s.c.)
injection results in sustained accumulation of the compound in
brain parenchyma, resulting in the largest total drug exposure
(6272 ng*hr/mL) compared to other routes of administration.
Notably, s.c. SR1 reached a peak brain concentration of 180 ±
100 nM (Cmax) 2 hr following s.c. injection and remained above
100 nM for several hours, providing a wide and reliable window
for experimental manipulation (Figures S1D and S1E, Table
S1). We confirmed the functional blockade of CB1 signaling by
harvesting cortical brain tissue from mice treated with this
regimen and measuring CB1 receptor activity by GTPgS assays
(Figure S1F; vehicle, EC50 = 8.9 ± 1.6 nM; SR1, EC50 = 26.0 ±
2.8 nM; t = 5.481, df = 8, p = 0.001). These results identify s.c.
treatment with 10 mg/kg SR1 and i.p. treatment with 10 mg/kg
WWL123 as optimal for CB1 receptor antagonism andABHD6 in-
hibition in mice, respectively.
ABHD6 Blockade Reduces PTZ-Induced Seizures
PTZ induces epileptiform seizures in healthy mice, typified by
progression through increasingly severe stages of seizure lead-
ing to death in a subset of individuals. Mice were pretreated
with either vehicle or 10 mg/kg WWL123, they were treated
with 50 mg/kg PTZ, and behavioral seizures were captured by
video recording. PTZ induced seizures that progressed from hy-
poactivity (stage 1) to partial clonus (stage 2) and to generalized
clonus (stage 3), culminated in global tonic-clonic (GTC) seizures
(stage 4), and were associated with death in 11% of cases. Pre-
treatment with WWL123 blocked seizure-related mortality,
reduced the severity of seizure behaviors (Figure 1A), reduced
the number of GTC seizures per mouse (from 1.90 ± 0.28 to
0.60 ± 0.22, Figure 1B), and also reduced the frequency of
myoclonic (MC) seizures (11.05 ± 0.51 to 7.29 ± 0.84, Figure 1C).
Note that ABHD6 blockade is not effective against stronger sei-
zures induced by 70 mg/kg PTZ (Figure S2A–S2D) or in a status-
epilepticus-like state induced by 30 mg/kg kainate (Figures S2E
and S2F).
To measure the electrographic changes between PTZ-treated
mice and PTZ+WWL123-treated mice, we recorded electrocor-
ticograms (ECoG) with bilateral epidural screw electrodes (see
Experimental Procedures) in the following brain areas: primary
somatosensory cortex (ECoG), cortical local field potentials in
layer V frontal cortex (LFPCTX), and hippocampal local field
potential in CA1 (LFPHIP) with fine-wire depth electrodes refer-
enced to a screw electrode over the olfactory bulb. Two days
after recovery from surgery, the mice were administered PTZ,
either with or without a 4 hr pretreatment with WWL123. Both
mice receiving PTZ and mice receiving PTZ+WWL123 ex-
perienced a GTC episode (with behaviors corresponding to
stage 4) within the first 10 min after PTZ administration, with
epileptiform activity evolving in all channels simultaneously out
of background EEG. Similarly, both groups experienced
AD
E
B C Figure 1. ABHD6 Blockade Decreases PTZ-
Induced Seizure Incidence and Severity
(A) Mice pretreated with WWL123 (n = 33) experi-
enced less severe PTZ-induced seizures (as
calculated by the latencies to Stage 2–4, see
methods), (B) fewer global tonic-clonic (GTC) sei-
zures, and (C) fewer myoclonic (MC) seizures,
compared to mice pretreated with vehicle (n = 37).
Results represent pooled data from all experi-
ments performed on C57BL/6 males in this
study. One week after surgical electrode implan-
tation, mice were treated with (D) PTZ or (E)
PTZ+WWL and EEG measurements were re-
corded. Condensed EEG (black) with corre-
sponding EMG (red) is presented at the top, and
3 myoclonic seizures, along with the onset and
end of the GTC seizures, are presented in greater
detail below. Myoclonic seizures were accompa-
nied by behavioral myoclonus (triangles). Fewer
myoclonic seizures were observed in mice pre-
treated with WWL123. GTC seizures observed in
mice receiving either PTZ or PTZ+WWL were
similar in nature. Fisher’s T-Test was used for
post-hoc analyses with *p < 0.05, **p < 0.01, ***p <
0.001. Error bars show SEM.
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preceded the GTC episode; however, the group pretreated with
WWL123 had fewer myoclonic seizures (Figures 1D and 1E). We
conclude that WWL123 reduces the frequency and severity of
PTZ-induced seizures and protects against seizure-related
death. Video-EEG monitoring confirmed that electrographic fea-
tures of PTZ-induced seizures were similar between treatments
and that no electrographic seizureswithout behavioral correlates
were seen in either group. Therefore, to minimize the confound-
ing effect of surgery, further studies were performed using
behavioral observation.
The Anticonvulsive Effects of WWL123 Involve GABAA
and Not CB1 or CB2 Receptors
To test the hypothesis that the antiepileptic effect of WWL123 is
due to increased CB1 signaling, we tested the effect of WWL123
on PTZ-induced seizures in WT and Cnr1/ mice. The protec-
tive effect of ABHD6 blockadewas retained inCnr1/mice (Fig-
ure 2A) across measures of seizure susceptibility, number of
GTCs, and number of MCs, without interaction between geno-Neuron 83, 361–type and treatment (see Table S3 for
full statistical testing results). To rule out
the involvement of CB2 receptors, we
testedWWL123 on PTZ-induced seizures
in Cnr2/ mice. Similar to what we
observed in Cnr1/ mice, the protective
effect of WWL123 on seizure susceptibil-
ity and MC was preserved in Cnr2/
mice (Figure 2B), without interaction
between genotype and treatment, but in
this experiment WWL123 did not reduce
GTCs in either WT or Cnr2/mice (Table
S3). It was our observation that GTCswere generally the most variable measure between separate ex-
periments. We conclude that the protective effect of ABHD6
blockade is independent of CB1 and CB2 receptors.
Recent reports have described a direct interaction between
2-AG and the GABAA receptor (Baur et al., 2013; Sigel et al.,
2011); therefore, we tested whether GABAA receptors are
required for the anticonvulsive effect of ABHD6 blockade by
cotreating with WWL123 and the GABAA antagonist picrotoxin.
Using a dose of 1 mg/kg picrotoxin, below the dose range
(>5 mg/kg) required to produce seizures on a single dosing
(Nutt et al., 1982), animals were treated with WWL123 or vehicle
(4 hr prior to receiving PTZ), and then with picrotoxin (1 mg/kg,
i.p.) or vehicle (5 min prior to receiving PTZ). As expected, picro-
toxin did not exacerbate PTZ-induced seizures (Figure 2C);
however, when GABAA receptors were blocked by picrotoxin,
WWL123 no longer reduced seizure susceptibility, GTCs, and
MC. Statistical analysis of these results indicate an interaction
effect between picrotoxin and WWL123 in both seizure suscep-
tibility and MC, and a trend in GTCs (Table S3). This result sug-
gests that the anticonvulsant quality of ABHD6 inhibition in371, July 16, 2014 ª2014 Elsevier Inc. 363
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Figure 2. The Antiepileptic Effect of ABHD6
Inhibition Is Independent of Cannabinoid
Receptors and Is Blocked by GABAA Antag-
onism
(A)WT (vehicle, n=13;WWL123, n=7) andCnr1/
mice (vehicle, n = 16; WWL123, n = 17) were pre-
treated with vehicle orWWL123, and then seizures
were induced by PTZ. The antiepileptic effect of
WWL123 was intact in Cnr1/mice as measured
by seizure susceptibility, number of GTCs and
rate of MC.
(B) WT (vehicle, n = 13; WWL, n = 10) and Cnr2/
mice (vehicle, n = 10; WWL123, n = 9) were pre-
treated with vehicle or WWL123, and seizures
were induced by PTZ. WWL123 reduced seizure
susceptibility, and MC, but failed to reduce GTCs
in either WT or Cnr2/ mice.
(C) WT mice were pretreated with vehicle/vehicle
(n = 19), WWL123/vehicle (n = 16), vehicle/picro-
toxin (n = 15), or WWL123/picrotoxin (n = 16), and
then seizures were induced by PTZ. The antiepi-
leptic effect of WWL123 was abolished by picro-
toxin in all three measures.
(D) Proposed mechanism: ABHD6 blockade in-
creases synaptic concentration of 2-AG, resulting
in increased activation of GABAA receptors which
exerts antiepileptic effects. Fisher’s T-Test was
used for post-hoc analyses with *p < 0.05, **p <
0.01, ***p < 0.001. Error bars show SEM.
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ABHD6 Controls SeizuresPTZ-induced epileptiform seizures is probablymediated through
GABAA receptors (see model in Figure 2D).
R6/2 Mice Experience Electrographic and Behavioral
Seizures
R6/2 mice are known to experience both spontaneous and
audiogenic seizures (Cepeda-Prado et al., 2012; Mangiarini
et al., 1996), yet neither qualitative nor quantitative analysis of
spontaneous seizures or of the possible etiology of these sei-
zures is available. To determine how electrographic features of
seizures correlate with observed behaviors, we performed EEG
recordings in tandem with video recording. ECoGs were re-
corded with screw electrodes placed bilaterally over frontal cor-
tex, and LFPs were recorded with fine-wire depth electrodes364 Neuron 83, 361–371, July 16, 2014 ª2014 Elsevier Inc.placed bilaterally superficial to CA1,
referenced to a screw electrode over
the olfactory bulb. Animals were given
5–7 days to recover after surgeries and
were then monitored on two consecutive
days for 6 hr intervals. Spontaneous
seizures were captured in this manner in
three separate R6/2 mice. Figure 3A
shows a representative example of an
EEG accompanying a spontaneous
behavioral seizure. The electrographic
and behavioral onsets of the seizure
were closely time-locked, seizure behav-
iors persisted throughout the entire elec-
trographic seizure, and after the seizure
there was both postictal suppression onthe EEG and a behavioral pause (Figure 3B). Furthermore, similar
behavioral findings were observed in mice with and without
surgical procedures, indicating that surgeries did not change
the nature of the seizures in R6/2 mice; thus, further studies
were performed using behavioral observation (see discussion
in Experimental Procedures).
Electrographic and Histological Abnormalities in R6/2
Hippocampus
LFP recordings from hippocampi (Figures 4A–4C) revealed inter-
ictal epileptic discharges in R6/2 but not WT mice, consisting of
high amplitude (>3 mV), sharply contoured complexes that tran-
siently disrupted ongoing hippocampal activity (suppression)
and were associated with high-frequency oscillations (fast
30
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3 Hindlimb extension, episthotonus
4 Early rearing
5 Forelimb clonus
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Figure 3. R6/2 Mice Experience Spontaneous Electrographic Seizures with Corresponding Seizure Behaviors
(A) Representative compressed electroencephalogram from cortical lead depicting a spontaneous electrographic seizure in an R6/2 mouse, with seizure be-
haviors identified at the time of occurrence (numbers). Background EEG is shown before seizure onset, evolves into rhythmic, sharply contoured spikes, and
resolves with clear postictal suppression accompanied by a behavioral pause; calibrator depicts 0.0005V, 20 s.
(B) Time-expanded EEG recording calibrator depicts 5 s, 0.0005V.
Neuron
ABHD6 Controls Seizuresripples), two criteria for hippocampal epileptic discharge (Bragin
et al., 1999; Engel et al., 2009). We reviewed EEG for epileptic
activity, which we defined as sharply contoured spikes that devi-
ated by more than three standard deviations from root-mean-
square (rms) of background activity. Unlike our findings in
hippocampus, we did not find epileptic activity in cortical leads
except in association with larger hippocampal spikes. Epileptic
complexes were not seen in recordings of WT mice. Interictal
spikes are associated with network hyperexcitability and are
consistent with an increased risk of partial-onset seizures.
We stained for anatomical indices of synaptic excitability in
hippocampal areas CA1, CA2, and CA3 and found increased
vGlut1 expression in R6/2 mice compared to wild-type mice
(one way ANOVA, CA1: p = 0.02; CA2: p = < 0.001; CA3 p =
0.004), while vGAT expression remained unchanged (Figures
4D–4F). The imbalance of these markers suggests increased
excitability without a corresponding increase in inhibitory tone.
While disturbances in the eCB system have been well described
in the striatum and cortex of R6/2 mice, the state of eCB system
in the hippocampus of this mouse line has not been reported.We
found a small increase in ABHD6 immunoreactivity in the CA1
and CA2 regions of R6/2 mice compared to wild-type mice (Fig-
ures S3A and S3B), whereas CB1 was decreased specifically in
vGlut1-positive pixels, suggesting a selective decrease in gluta-
matergic terminals (Figures S3C–S3F). NPY inhibits excitatory
neurotransmission (Colmers et al., 1988), by synapsing onto pre-synaptic mossy fiber (CA2/CA3) and Schaffer collateral (CA1)
terminals (Baraban et al., 1997), and exerts powerful anticonvul-
sant effects through Y5 receptors (Marsh et al., 1999; Vezzani
et al., 1999; Woldbye et al., 1997). Deletion of Npy has been
associated with temporal seizures (Baraban et al., 1997;
Erickson et al., 1996) that are blocked by both intraventricular
administration of NPY (Woldbye et al., 1996) and NPY gene
therapy (Noe` et al., 2008). We measured a profound reduction
in NPY immunoreactivity in the hippocampus of R6/2 mice,
compared with wild-type, (p = 0.004) (Figures 4G and S4),
suggesting a candidate mechanism (Figure 4H) for epileptogen-
esis in R6/2 mice. Together, these findings support our strategy
to test the utility of ABHD6 blockade in a genetic model of sei-
zures featuring electrographic and histological abnormalities in
hippocampus.
ABHD6 Inhibitor Blocks Behavioral Seizures in R6/2
Mice in a CB1-Independent Manner
To test whether behavioral seizures exhibited by R6/2 mice
are controlled by chronic pharmacological blockade of the
ABHD6/CB1 arm of the eCB signaling system, we treated these
mice with a daily injection of vehicle, SR1, or WWL123 begin-
ning at 4 weeks of age (Figure 5A). Note that we did not
observe overt side effects associated with chronic WWL123
administration during the 8 weeks of treatment period and
did not observe any sign of psychomotor impairment, asNeuron 83, 361–371, July 16, 2014 ª2014 Elsevier Inc. 365
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Figure 4. Electrographic and Histological Abnormalities in the Hippocampus of R6/2 Mice
Representative example of hippocampal theta/gamma oscillations (A) and two representative examples of interictal discharges in R6/2 mice (B–C). Calibrator
depicts 100 ms, 5 mV (wideband) or 0.5 mV (ripple and fast ripple). Discharges in R6/2 mice exceeded 3mV in hippocampal leads (maximal voltage:
B = 4.5 mV, C = 5.0 mV), a common criterion for epileptic discharge, and featured higher amplitude in ripple components (maximal peak-to-peak amplitude:
A = 202 mV; B = 587 mV; C = 904 mV) as well as a fast ripple component not observed in theta/gamma (maximal peak-to-peak amplitude: B = 876 mV,
C = 847 mV).
(D) Representative 203 images of vGLUT1 and vGAT staining in CA2 depict increased intensity of vGLUT1 staining in the stratum lucidum of R6/2 mice.
(E and F) vGLUT1 immunoreactivity was increased in the stratum lucidum of CA1, CA2, and CA3 (E), but these changes were not accompanied by a corre-
sponding increase in vGAT immunoreactivity (F).
(G) Loss of NPY immunoreactivity is detected throughout the hippocampus in R6/2 mice (for details see Figure S6).
(H) Model depicting the NPY component of the hippocampal circuit; NPY interneurons provide presynaptic inhibition of mossy fiber (MF) and Schaffer collateral
(SC) fibers, and reduction of this inhibition is associated with increased excitatory signaling. Measurements were made after thresholding to mean+SD (vGLUT1
and vGAT), or mean + 2*SD (NPY), as determined by the percent of pixels for each stain which represented staining of target proteins. Scale bar depicts 50 mm.
Error bars show SEM, and Fisher’s t test is indicated as *p < 0.05, **p < 0.01, ***p < 0.001.
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ABHD6 Controls Seizuresmeasured by open field (Figure S5A), novel object recognition
(Figure S5B and S5C), and elevated plus maze (Figures S5D
and S5E). We found that SR1 increased, and WWL123 blocked,
the incidence of spontaneous behavioral seizures in R6/2 mice
(Figures 5B and 5C; vehicle = 31%, SR1 = 80%, WWL123 =
0%; 2 3 3 contingency table analyzed by Fisher’s Exact Test,
p = 0.023). There was no effect (vehicle = 64.4 ± 7.5 s;
SR1 = 60.3 ± 20.1 s, p = 0.89) on duration of spontaneous sei-
zures in response to chronic SR1 treatment vehicle = 64.4 ±
7.5 s; SR1 = 60.3 ± 20.1 s, p = 0.89). These results indicate
that chronic ABHD6 inhibition is effective against spontaneous
seizures in a genetic model of epilepsy and that no tolerance
develops to prolonged treatment with WWL123. The involve-
ment of GABAA receptors could not be tested in R6/2 mice
because chronic low-dose GABA antagonists result in kindling
in WT mice (White, 2003).366 Neuron 83, 361–371, July 16, 2014 ª2014 Elsevier Inc.To assess the mechanism of antiepileptic action of ABHD6
blockade in R6/2 mice, we acutely treated 9-week-old drug-
naive mice with a single injection of vehicle, SR1, WWL123, or
SR1+WWL123, and monitored the animals for 6 hr with video
recording (Figures 5D and 5E). Videoswere scored for behavioral
seizures of Racine grade 4–6. Similar to what we observed with
chronic treatment, acute treatment with WWL123 prevented sei-
zures and acute treatment with SR1 increased the number of sei-
zures observed over 6 hr. However, SR1 treatment did not
antagonize the effect of WWL123, suggesting the absence of
CB1 receptor-involvement in the protective effect of WWL123
(vehicle = 8%, SR1 = 63%, WWL123 = 0%, SR1+WWL123 =
0%; 2 3 4 contingency table analyzed by Fisher’s Exact Test,
p = 0.006). Here, too, the involvement of GABAA receptors could
not be tested with picrotoxin because of its short duration of
action compared with WWL123 or SR1, and because of the
AB C
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Figure 5. ABHD6 Blockade Blocks Spontaneous Behavioral Sei-
zures in R6/2 Mice in a CB1-Independent Manner
(A) R6/2 mice were treated with WWL123, SR141716 (SR1), or vehicle daily
starting at 4 weeks of age. Six hour video-recorded seizure observations were
performed after the daily drug treatment at 7 weeks and 9 weeks of age, and
the data were pooled in order to obtain a more accurate estimate of seizure
incidence using multiple observations. Seizure incidence was measured by
scoring seizure behaviors corresponding to Racine 4–6 for i.p. vehicle (n = 6),
s.c. vehicle (n = 6), 10mg/kg i.p.WWL123 (n = 5), and 10mg/kg s.c. SR1 (n = 5);
the two vehicle groups did not differ from each other and were thus pooled for
analysis.
(B) SR1 treatment increased seizure incidence relative to vehicle treatment,
and WWL123 treatment abolished seizures.
(C) Seizure duration was unchanged between vehicle and SR1-treated mice
under this chronic treatment regimen. In order to assess mechanism of action,
drug-naive R6/2 mice were treated acutely with vehicle (n = 12), SR1 (n = 8),
WWL123 (n = 8), or SR1+WWL123 (n = 8), and seizure incidence was scored
during the single six hour observation.
(D) Acute SR1 treatment increased seizure incidence relative to acute vehicle
treatment, and acute WWL123 treatment abolished all seizures, even in mice
cotreated with SR1.
(E) Seizure duration was not statistically tested because only one seizure
was captured in the vehicle group (vehicle = 20 s; SR1 = 51 ± 34 s). Error bars
show SEM.
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ABHD6 Controls Seizureslong observation window needed to reliably capture sponta-
neous seizures. Together with results obtained in the PTZ-
induced seizure model, this result suggests that the antiepileptic
activity of ABHD6 inhibition operates through a CB1-indepen-
dent mechanism.DISCUSSION
ABHD6 is a newly identifiedmember of the eCB signaling system
responsible for controlling the postsynaptic production of 2-AG
(Marrs et al., 2010). We now show that ABHD6 blockade by
WWL123 exerts an antiepileptic effect in PTZ-induced epilepti-
form seizures and spontaneous seizures in R6/2 mice. We found
that the antiepileptic activity of ABHD6 blockade against PTZ-
induced seizures is independent of both CB1 and CB2 receptors,
and probably dependent on GABAA receptors. A direct and pos-
itive allosteric modulation of GABAA receptors by 2-AG has been
demonstrated (Sigel et al., 2011), and subsequent molecular
modeling paired with site-directed mutagenesis identified the
inner (cytosolic) leaflet of the b2 subunit of GABAA as the binding
site for 2-AG (Baur et al., 2013). Based on this evidence, postsyn-
aptic production of 2-AG could signal through GABAA receptors
in an autocrine manner, and the postsynaptic localization of
ABHD6 places this enzyme in an ideal location to control the
availability of 2-AG at GABAA receptors. Note that we also
cannot exclude the possibility that the antiepileptic effect of
ABHD6 blockade is mediated by a molecular species besides
2-AG, as ABHD6 has other known substrates (Navia-Paldanius
et al., 2012; Thomas et al., 2013). Also note that an indirect effect
of 2-AG on GABAA mediated through CB1 receptors is unlikely
because CB1 activity decreases GABA release (Wilson and Nic-
oll, 2001) and because the antiepileptic effect of WWL123 is not
lost in Cnr1/ mice or after treatment with SR1.
There are major drawbacks to currently available therapeutic
approaches for the treatment of epilepsy, including tolerance
to the efficacy of antiepileptic drugs and increased likelihood
of dose-related side effects, both of which reduce their clinical
utility. When treating mice daily with WWL123 for 5 weeks,
we did not observe tolerance to chronic ABHD6 blockade,
in contrast to what is seen after chronic treatment with CB1
receptor agonists and with MGL inhibitors (Blair et al., 2009;
Schlosburg et al., 2010). Furthermore, we did not observe
signs of motor or cognitive impairment typically associated
with both CB1 agonists and to a lesser degree with MGL inhib-
itors, nor did we observe sedation as is seen with GABAA
agonists (van Rijnsoever et al., 2004). Lack of tolerance and
the absence of measurable off-target behavioral effects might
be due to the spatiotemporal specificity of ABHD6 blockade
that is derived from a combination of the activity-dependence
of 2-AG synthesis (Di Marzo, 2011; Stella and Piomelli, 2001)
and its weak enzymatic activity that controls only local levels
of 2-AG (Marrs et al., 2011, 2010). Together, these findings
suggest that ABHD6 inhibitors might exhibit a favorable safety
profile and be amenable to long-term use for the treatment of
seizures.
Among HD patients, individuals that carry more than 60 CAG
repeats in the huntingtin gene begin exhibiting symptoms in their
teens (or even younger as the number of repeats increases)
(Andrew et al., 1993). This subset of patients are afflicted by
juvenile HD (JHD), an early and more aggressive variant of the
disease that uniquely features myoclonic seizures in 38% of
patients (Cloud et al., 2012), which are refractory to standard
antiepileptic medications (Gonzalez-Alegre and Afifi, 2006).
Therefore, epilepsy is emerging as a major comorbidity andNeuron 83, 361–371, July 16, 2014 ª2014 Elsevier Inc. 367
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about the molecular mechanisms underlying seizure incidence
in this patient population. R6/2mice recapitulate several aspects
of an early-onset, rapidly progressive JHD phenotype, includ-
ing both spontaneous seizures and early death (Bates and
Woodman, 2009; Mangiarini et al., 1996). Here we show that
behavioral seizures in R6/2 mice correspond to electrographic
seizures and that ABHD6 blockade controls these seizures
through a CB-independent mechanism. Our initial charac-
terization of the seizures exhibited by R6/2 mice suggests
hippocampal involvement. Interictal discharges with amplitude,
morphology, and frequency components characteristic of
epileptic discharges were observed in hippocampal leads. Since
the purpose of the current study was to explore the anticonvul-
sive and antiepileptic efficacy of ABHD6 inhibition, follow-up
studies are required. We note that our recordings do not rule
out an epileptic focus outside of the hippocampus and that
recordings with higher spatial and temporal resolution are
required, although this approach is technically challenging
due to the hypersensitivity to anesthesia displayed by R6/2
mice and the fact that they experience anesthesia-related death
with long surgery times (see Experimental Procedures). Addi-
tional, longer-duration recordings with quantitative analysis
are required to fully characterize the epileptic phenotype of
R6/2 mice.
We observed a striking reduction of NPY expression through-
out the hippocampus, and NPY deletion has been shown to
result in temporal seizures that in turn can be rescued by intra-
ventricular injection of exogenous NPY (Baraban et al., 1997;
Erickson et al., 1996; Woldbye et al., 1996). Reduced NPY in
R6/2mice is somewhat paradoxical, since seizure activity is typi-
cally associated with increases in hippocampal NPY expression
(Vezzani et al., 1994). NPY interneurons provide presynaptic in-
hibition at mossy fibers (CA2/3) and at Shaffer collaterals
(CA1), both of which are excitatory, and accordingly our results
show increased expression of vGLUT1, but not vGAT, in CA1,
CA2, and CA3 stratum pyramidale. Mutant huntingtin dysregu-
lates the expression pattern of hundreds of genes (Luthi-Carter
et al., 2002, 2000), including many members of the eCB family.
Therefore, it is possible that mutant huntingtin decreases hippo-
campal NPY expression, which in turn results in a disinhibition
of both Shaffer collaterals and mossy fibers. The resulting
increased excitatory drive in the hippocampus could ultimately
manifest as seizure activity.
In summary, this study identifies the recently described 2-AG
hydrolase ABHD6 as a potential therapeutic target for epilepsy.
To characterize the broader utility of this therapeutic strategy,
it is necessary to outline the types of seizures that are sensitive
to ABHD6 blockade. ABHD6 inhibitors should be systematically
tested against classical models such as maximal electroshock,
against acquired epilepsies such as traumatic brain injury
(TBI)-induced seizures (White, 2003), as well as in models of
treatment-resistant seizures such Dravet mice (Cheah et al.,
2012; Kalume et al., 2013). Further experiments are needed to
thoroughly demonstrate that ABHD6 inhibition proceeds directly
through GABAA by increasing the local levels of 2-AG and its
availability at GABAA. Finally, given the superadditive GABAA re-
sponses induced by 2-AG and diazepam (Baur et al., 2013; Sigel368 Neuron 83, 361–371, July 16, 2014 ª2014 Elsevier Inc.et al., 2011), an isobolic study between these two drugs in an
induced seizure paradigm would establish whether both thera-
peutic approaches could be used synergistically in vivo for anti-
epileptic therapy.
EXPERIMENTAL PROCEDURES
Animals
All animal procedures were approved by the Institutional Animal Care and Use
Committee for the University of Washington. For PTZ experiments, we used
male C57Bl/6 mice. WT and Cnr1/ mice (Marsicano et al., 2002) were
bred in our colony, and Cnr2/ mice (Deltagen) were gifted to us by Ken
Mackie. Results obtained with animals treated with vehicle and WWL123
were generated using littermates within genotype. R6/2 mice present signifi-
cant challenges for breeding, as all females and approximately half of males
are sterile. Because these difficulties are compounded on a C57Bl/6 back-
ground, spontaneous behavioral seizure assays in R6/2 mice were performed
on amixed CBA-C57Bl/6 background inmale and female littermates, and gen-
ders were balanced between cohorts. R6/2 (6- to 8-week-old) males and wild-
type females (CBA-C57Bl/6) were bred to maintain the R6/2 colony (114 CAG
repeats; sequenced at Laragen, Culver City, CA). Mice had ad libitum access
to food and water and were given additional wet food mash at 9 weeks of age.
All R6/2 cages were provided with enrichment, and mice were not handled
prior to experiments, other than to change cages or perform injections for
chronic studies.
Drugs and Antibodies
SR141716 (SR1) was supplied by NIDA drug supply,WWL123 (WWL) was syn-
thesized by the Cravatt Laboratory (Bachovchin et al., 2010), pharmasolve-n-
methyl-2-pyrrolidone (Pharmasolve) was purchased from ISP Technologies
(Columbia, MD), and Cremophor RH40 and Lutrol F68 were purchased from
BASF (FlorhamPark, NJ). Antibodies used for immunohistochemistry are listed
in Table S2.
Drug Pharmacokinetics and Target Validation
See Supplemental Experimental Procedures for detailed description of phar-
macokinetic, GTPgS, and affinity-based protein profiling (ABPP) procedures.
PTZ-Induced Seizures and Monitoring
We performed i.p. injections of 50 or 70 mg/kg pentylenetetrazole (PTZ;
Sigma, MO, USA) and then immediately placed animals in a 10’’ 3 18’’ 3
18’’ chamber with video recording (Zhang et al., 2010). Seizures were scored
by two blinded observers according to a modified Racine scale designed spe-
cifically for PTZ-induced seizures in mice (Ferraro et al., 1999):
Stage 1: Hypoactivity culminating in behavioral arrest with contact be-
tween abdomen and the cage.
Stage 2: Partial clonus (PC) involving the face, head, or forelimbs.
Stage 3:Generalized clonus (GC) including all four limbs and tail, rearing, or
falling.
Stage 4: Generalized Tonic-Clonic seizure (GTC)
Seizure susceptibility was calculated from the latencies to Stage 2-4, as pre-
viously described (Ferraro et al., 1999). Susceptibility scores are reported as a
fraction of the average score for mice receiving only PTZ.
Susceptibility score=
X
0:2  1
latency to PC
+ 0:3  1
latency to GC
+ 0:5  1
latency to GTC

Myoclonic seizures (MC) and GTCs were also counted independently,
because the seizure susceptibility score does not take into account the num-
ber of seizures. GTCs are reported as total number observed over 30 min after
injection with PTZ. Because GTCs temporarily suppressed MCs, we counted
MCs prior to the first GTC and reported them as MC/min, or in the case of
animals that did not experience GTCs, we reported the rate of MCs over the
Neuron
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rienced GTCs.
Spontaneous Seizure Assays
Wild-type and R6/2 mice were treated with 10 mg/kg SR1 (s.c.), 10 mg/kg
WWL123 (i.p.), or vehicle (Pharmasolve:Cremophor RH40:1% Lutrol F68
[1:9:40]). Daily chronic treatment began at 4 weeks of age, 1 week after
mice were weaned. Spontaneous seizure observations were conducted in
7-week-old (chronic) and 9-week-old (chronic and acute) R6/2 and wild-type
littermates. Mice were treated with SR1, WWL123, or SR1 + WWL123; SR1
was administered 90 min beforehand, and WWL123 was administered
120 min beforehand. Following injection, mice were placed directly into a
10’’ 3 18’’ 3 18’’ plexiglass box and monitored for spontaneous behavioral
seizures by video recording for 6 hr, then returned to their home cage.
Behavioral seizures were scored from video recordings on the Racine scale
(Racine, 1972) (1 =mouth and facial movement; 2 = head nodding; 3 = forelimb
clonus; 4 = rearing with forelimb clonus; 5 = rearing and falling with forelimb
clonus; 6 = tonic seizure followed by death). Videos were scored by at least
two blinded observers who scored only behavioral seizures with Racine
score of 4–6.
We noted a pronounced effect of the surgeries on the progressive pheno-
type of R6/2 mice. Specifically, only 54% of R6/2 mice survived ketamine/
xylazine anesthesia, and overall, the genotype displayed hypersensitivity to
anesthetics and required reduced dosing. For those that survived anesthesia,
mice which did not have tremors or obvious motor impairment before the sur-
geries showed clear acceleration in phenotype after the surgeries with hunch-
ing, tremors, ataxia, and hypoactivity. In addition, the average survival of R6/2
mice was 1 week after surgery, which shortened their lifespan from the normal
phenotype by at 2-4 weeks. Spontaneous seizures were not observed in the
72 hr window after surgery, suggesting a temporary effect of anesthesia on
seizure incidence. Since our aim was to study spontaneous seizures, which
most accurately model the seizures occurring in juvenile HD patients, EEG sur-
geries were deemed confounding for accurate interpretation of our results and
subsequent data was gathered by monitoring and grading behaviors without
concomitant EEG. It should be noted that our monitoring protocol does not
provide information on smaller seizures (Racine 1–3), or on electrographic sei-
zures not resulting in seizure behaviors. Behaviors corresponding to Racine
1–3 were deliberately excluded because the authors felt that without concom-
itant EEG, which is not technically feasible due to the aggressive phenotype of
the mice, scoring minor behaviors would lead to substantial error.
Semiquantitative Immunohistochemistry
Mice were euthanized 3 days after seizures and perfused with paraformalde-
hyde (4% in PBS); brains were extracted, postfixed for 24 hr, and cryopro-
tected in 15% sucrose (24 hr) followed by 30% sucrose (48 hr). Staining
was performed as described in Horne et al. (2013). Images were collected
on a Leica SP1 Confocal Laser Scanning microscope with a 633 oil objec-
tive, and on an Olympus Fluoview-1000 Confocal microscope equipped with
an automated stage and a 203 air or 633 oil objective. Images were analyzed
using automatedmacros in a Fiji distribution of ImageJ (Schindelin et al., 2012).
Thresholding was performed to remove background staining (threshold =
mean + SD for all stains except NPY, threshold = mean + 2*SD for NPY),
and mean intensity of remaining pixels was calculated, a method we have pre-
viously validated (Horne et al., 2013).
Surgeries and EEG Measurements
Electroencephalographs (EEGs) were performed as described by Oakley et al.
(2009). Under ketamine/xylazine (130/8.8 mg/kg) anesthesia 6- to 8-week-old
mice were secured in a stereotactic headframe (David Kopf instruments) and
using aseptic techniques a midline incision was made over the cranium before
small burr holes were drilled for electrode placement bilaterally at 3 positions:
LFP (A-P: +1.2 mm; lateral: ±3 mm), EcoG (A-P: 0.7 mm; lateral: ±2.25 mm),
and Hippocampal (A-P: 2.02 mm; lateral: ±1.25 mm). Higher-impedance
stainless steel fine-wire electrodes (.003 inches uncoated, 0.0055 inches
coated; A-M systems) were used for hippocampal and LFP depth electrodes
and targeted to stratum radiatum of CA1 and layer V, respectively. Lower-
impedance stainless steel screws (Amazon Supply) were used for ECoG re-cordings. Reference electrodes were placed over the olfactory bulb and
ground was either a fully bared stainless steel fine wire or screw placed over
the midline cerebellum. All electrodes were secured to the head with dental
cement and connected to electrode interface boards (Neuralynx) for recording
purposes, and placement was verified by Nissl stain. Animals were allowed to
recover for one week following surgery. On the day of recordings, implanted
mice were housed in a plexiglass box and EEG recordings were collected
using a RZ2D bioamp processor (Tucker Davis Technologies) sampled at
either 6 or 1.5 kHz and further analysis was conducted offline. Offline digital
filtering was performed with Hamming-window based FIR filter for wide-
band (1–900 Hz), ripple (150–250 Hz), and fast ripple (300–600 Hz). Seizures
were identified by characteristic sharp, rhythmic patterns consisting of
repeated epileptic discharges followed by suppression of background activ-
ities. Simultaneous video recording was used to associate seizure behaviors
with EEG patterns.
Data Analysis
Data were analyzed and graphed using PRISM 5 (GraphPad). All group tests
for statistical significance in Figures 1-4 were performed using one-way
ANOVA, except for interaction testing which was performed with two-way
ANOVA. Post-hoc tests were analyzed by Fisher’s T-Test. Contingency tables
(Figure 5) were analyzed in R (http://cran.r-project.org), using Fisher’s Exact
test. Error bars depict standard error of the mean. EEG data were analyzed
offline using Igor Pro 5.0 (Wavemetrics). Immunohistochemistry was analyzed
using automated and unbiased macros written in the Fiji release of ImageJ
(http://fiji.sc/Fiji).
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